Qureator is pleased to announce that CEO Dr. Kyu Baek will present the company’s newest innovation—the Vascularized Tumor Immune Microenvironment (vTIME) platform—at the CSEM Next-Gen Organ-on-Chips & Organoids Workshop on February 14th in Basel.
Qureator is proud to announce that its pioneering work on age-related macular degeneration (AMD) has been featured as the cover article in Advanced Materials Technologies.
Qureator is proud to be featured in a recent update from our collaborator, Professor Jonathan Sexton of the University of Michigan, highlighting the use of our Curiochip™ microphysiologic system in a cutting-edge platform for predicting drug-induced liver injury (DILI).
Qureator is excited to announce a new research collaboration with SillaJen Inc. to evaluate combination immunotherapy using BAL0891, a dual TTK/PLK1 inhibitor, with PD-1 immune checkpoint inhibitors.
Qureator was recently featured in The Chosun Daily for its cutting-edge human disease modeling platform that replicates complex tissue microenvironments using organ-on-a-chip technology.